China continues to lead Asia’s drug development, with other nations following China’s initiatives.
Small molecules and oncology remain as the most dominant within Asian drug development markets.
South Korea and India expand clinical trial activity while Japan shifts to multinational trials.
M&A occurs but remains a secondary channel to licensing across these markets; South Korea and Japan are primarily oriented toward out-licensing innovative assets to US/EU partners.
Small molecules and oncology remain as the most dominant within Asian drug development markets.
South Korea and India expand clinical trial activity while Japan shifts to multinational trials.
M&A occurs but remains a secondary channel to licensing across these markets; South Korea and Japan are primarily oriented toward out-licensing innovative assets to US/EU partners.
Report Scope
- This report talks about how other nations, including South Korea, Japan, and India, are following China's initiatives by enhancing innovation across the drug development lifecycle.
- These nations are deploying differentiated regulatory pathways to accelerate development and attract investment, increasing Asia’s strategic importance for global clinical, regulatory, and partnering strategies.
Table of Contents
- Executive Summary
- Introduction
- Regulatory Advancements
- Drug Development
- Therapy Area Focus: Oncology
- Biosimilars
- Innovators
- Clinical Trials
- Deals
- Key Takeaways
- Appendix:
- Abbreviations
- Related Reports
- Authors
- Contact the Publisher
